Posted by Michael Wonder on 24 Sep 2017
Roche receives EU approval of Tecentriq (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
22 September 2017 - Tecentriq provides a new treatment option for people with previously treated locally advanced or metastatic non-small cell cancer.
Roche today announced that the European Commission (EC) has granted a marketing authorisation for Tecentriq (atezolizumab) use as monotherapy for the treatment of people with locally advanced or metastatic non-small cell lung cancer (NSCLC) after they have been previously treated with chemotherapy regardless of PD-L1 status. People with EGFR-activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving Tecentriq. This approval is based on results from the large randomised Phase III OAK study and the randomised Phase II POPLAR study.
The Phase III OAK study showed that Tecentriq helped people in the overall study population live a median of 13.8 months–4.2 months longer than those treated with docetaxel chemotherapy (median OS: 13.8 vs 9.6 months; hazard ratio [HR] = 0.73, 95% confidence interval: 0.62, 0.87).
